Find Naporafenib manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

API Suppliers

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Lxh254, 1800398-38-2, Lxh-254, Lxh254 free base, N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, Pan-raf inhibitor lxh254
Molecular Formula
C25H25F3N4O4
Molecular Weight
502.5  g/mol
InChI Key
UEPXBTCUIIGYCY-UHFFFAOYSA-N
FDA UNII
15JL80DG6H

Naporafenib
Naporafenib is an orally available inhibitor of all members of the serine/threonine protein kinase Raf family, with potential antineoplastic activity. Upon administration, naporafenib binds to Raf proteins and inhibits Raf-mediated signal transduction pathways. This inhibits proliferation of Raf-overexpressing tumor cells. Raf protein kinases are critical enzymes in the Ras/Raf/MEK/ERK signaling pathway and are upregulated in a variety of cancer cell types. They play key roles in tumor cell proliferation and survival.
1 2D Structure

Naporafenib

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
N-[3-[2-(2-hydroxyethoxy)-6-morpholin-4-ylpyridin-4-yl]-4-methylphenyl]-2-(trifluoromethyl)pyridine-4-carboxamide
2.1.2 InChI
InChI=1S/C25H25F3N4O4/c1-16-2-3-19(30-24(34)17-4-5-29-21(12-17)25(26,27)28)15-20(16)18-13-22(32-6-9-35-10-7-32)31-23(14-18)36-11-8-33/h2-5,12-15,33H,6-11H2,1H3,(H,30,34)
2.1.3 InChI Key
UEPXBTCUIIGYCY-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CC1=C(C=C(C=C1)NC(=O)C2=CC(=NC=C2)C(F)(F)F)C3=CC(=NC(=C3)OCCO)N4CCOCC4
2.2 Other Identifiers
2.2.1 UNII
15JL80DG6H
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Lxh254

2.3.2 Depositor-Supplied Synonyms

1. Lxh254

2. 1800398-38-2

3. Lxh-254

4. Lxh254 Free Base

5. N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide

6. Pan-raf Inhibitor Lxh254

7. Naporafenib [inn]

8. 15jl80dg6h

9. 1800398-38-2 (free Base)

10. N-[3-[2-(2-hydroxyethoxy)-6-morpholin-4-ylpyridin-4-yl]-4-methylphenyl]-2-(trifluoromethyl)pyridine-4-carboxamide

11. 4-pyridinecarboxamide, N-(3-(2-(2-hydroxyethoxy)-6-(4-morpholinyl)-4-pyridinyl)-4-methylphenyl)-2-(trifluoromethyl)-)-

12. N-(3-(2-(hydroxyethoxy)-6-(morpholin-4-yl) Pyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)pyridine-4-carboxamide

13. N-{3-[2-(2-hydroxyethoxy)-6-(morpholin-4-yl)pyridin-4-yl]-4-methylphenyl}-2-(trifluoromethyl)pyridine-4-carboxamide

14. Lxh 254

15. K81

16. Unii-15jl80dg6h

17. Naporafenib [who-dd]

18. Chembl4583691

19. Lxh 254 [who-dd]

20. Schembl16094629

21. Bdbm88120

22. Gtpl10658

23. Bcp29080

24. Ex-a1846

25. Nsc807047

26. S8745

27. Akos037648965

28. At23218

29. Nsc-807047

30. Compound 15 [pmid: 31059256]

31. Ac-36207

32. Bl166445

33. Bs-16133

34. Hy-112089

35. Cs-0043317

36. Example 1156 [wo2014151616a1]

37. A16841

38. Us9694016, 1156

2.4 Create Date
2015-02-13
3 Chemical and Physical Properties
Molecular Weight 502.5 g/mol
Molecular Formula C25H25F3N4O4
XLogP33.2
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count10
Rotatable Bond Count7
Exact Mass502.18278978 g/mol
Monoisotopic Mass502.18278978 g/mol
Topological Polar Surface Area96.8 Ų
Heavy Atom Count36
Formal Charge0
Complexity709
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Pharmacology and Biochemistry
4.1 MeSH Pharmacological Classification

Antineoplastic Agents

Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)


Protein Kinase Inhibitors

Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)


Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty